Checkmate Pharmaceuticals Operating Income

Checkmate Pharmaceuticals (CMPI) currently reports a operating income of $-63M as of March 2022. That compares with $-43M in the prior-year period — down 45.9% year over year. Use the charts on this page to explore Checkmate Pharmaceuticals's operating income history and peer comparisons.

Checkmate Pharmaceuticals's operating income decreased from $-43M to $-63M — a 45.9% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Checkmate Pharmaceuticals reported $-63M in operating income as of March 2022. That compares with $-43M in the prior-year period — down 45.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-63M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Checkmate Pharmaceuticals, and consider following CMPI for alerts when major investors trade the stock.

Checkmate Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-63M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CMPI with unrelated industries.